Watch ZBIO. Know when insiders buy.
One email the day a filing lands. Free.
ZBIO
Zenas BioPharma, Inc.
28.30
+0.35 +1.27%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8BP/E —DIV YIELD —FCF YIELD -12.25%REV TTM —NET INCOME −$484.4MNET CASH $117.9M52W 15.20 – 43.17SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1M | — | — | −$107.7M | −$111.5M | — | -1.77 | −$57.2M | $0 | −$57.2M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$77.3M | −$81M | — | -1.46 | −$75.2M | $2K | −$75.2M | Aug 13 |
| Q4 2025 · Dec 31derived | $0 | −100.0% | — | −$238M | −$240.4M | — | -5.17 | −$52.4M | $0 | −$52.4M | Mar 16 |
| Q3 2025 · Sep 30 | $0 | — | — | −$52.6M | −$51.5M | — | -1.22 | −$41.1M | $0 | −$41.1M | Nov 12 |
| Q2 2025 · Jun 30 | $0 | — | — | −$55.2M | −$52.2M | — | -1.25 | −$41.7M | $0 | −$41.7M | Aug 13 |
| Q1 2025 · Mar 31 | $10M | — | — | −$37.3M | −$33.6M | — | -0.80 | −$37.1M | $18K | −$37.1M | Aug 13 |
| Q4 2024 · Dec 31derived | $5M | — | — | −$55.6M | −$52.6M | — | 16.94 | −$38.6M | $74K | −$38.6M | Mar 16 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$41M | −$38.6M | −208.4% | -5.02 | −$31.1M | $0 | −$31.1M | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$39.7M | −$38M | — | -24.23 | −$31M | $35K | −$31M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$27.6M | −$27.8M | — | -17.89 | −$19.1M | $22K | −$19.1M | Nov 12 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$24.8M | −$24.6M | — | -16.04 | −$15.4M | — | — | Mar 11 |
| Q3 2023 · Sep 30 | $50M | — | — | $35.6M | $35.6M | — | 1.96 | — | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $10M | — | −$383.1M | −$377.7M | -3777.4% | -8.44 | −$172.3M | $18K | −$172.4M | — | — |
| FY2024 · to Dec 31 | $5M | — | −$163.9M | −$157M | -3139.8% | -11.89 | −$119.7M | $131K | −$119.8M | — | — |
| FY2023 · to Dec 31 | $50M | — | −$37.1M | −$37.1M | -74.2% | -24.25 | −$30.5M | $17K | −$30.5M | — | — |
Every number comes from Zenas BioPharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.